140 related articles for article (PubMed ID: 37213608)
21. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
22. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
23. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
24. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous metastasis as a initial presentation in advanced non-small cell lung cancer and its poor survival prognosis.
Song Z; Lin B; Shao L; Zhang Y
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1613-7. PubMed ID: 22581263
[TBL] [Abstract][Full Text] [Related]
26. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China.
Lu J; Xu A; Wang J; Zhang L; Song L; Li R; Zhang S; Zhuang G; Lu M
BMC Health Serv Res; 2013 Jan; 13():37. PubMed ID: 23368750
[TBL] [Abstract][Full Text] [Related]
27. Distance from accessible specialist care and other determinants of advanced or unknown stage at diagnosis of people with non-small cell lung cancer: A data linkage study.
Tracey E; McCaughan B; Badgery-Parker T; Young J; Armstrong B
Lung Cancer; 2015 Oct; 90(1):15-21. PubMed ID: 26275475
[TBL] [Abstract][Full Text] [Related]
28. The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden.
Wood R; Taylor-Stokes G; Smith F; Chaib C
Qual Life Res; 2019 Jul; 28(7):1849-1861. PubMed ID: 30825160
[TBL] [Abstract][Full Text] [Related]
29. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
30. Does access to private healthcare influence potential lung cancer cure rates?
John TJ; Plekker D; Irusen EM; Koegelenberg CFN
S Afr Med J; 2017 Jul; 107(8):687-690. PubMed ID: 28809615
[TBL] [Abstract][Full Text] [Related]
31. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
32. Quality assessment using EQ-5D-5L after lung surgery for non-small cell lung cancer (NSCLC) patients.
Koide R; Kikuchi A; Miyajima M; Mishina T; Takahashi Y; Okawa M; Sawada I; Nakajima J; Watanabe A; Mizuguchi T
Gen Thorac Cardiovasc Surg; 2019 Dec; 67(12):1056-1061. PubMed ID: 31098867
[TBL] [Abstract][Full Text] [Related]
33. Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China.
Zhu D; Shi X; Nicholas S; Ma Y; He P
Cancer Med; 2021 Apr; 10(8):2914-2923. PubMed ID: 33749141
[TBL] [Abstract][Full Text] [Related]
34. Caregiver burden for informal caregivers of patients after surgical treatment of early-stage lung cancer.
Zhu S; Yang C; Mei W; Kang L; Li T; Li J; Li L
J Clin Nurs; 2023 Mar; 32(5-6):859-871. PubMed ID: 35869414
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
Cheng R; Zhou Z; Liu Q
Cancer Med; 2023 Mar; 12(6):7389-7397. PubMed ID: 36373001
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
37. Assessing health-related quality of life of patients with colorectal cancer using EQ-5D-5L: a cross-sectional study in Heilongjiang of China.
Huang W; Yang J; Liu Y; Liu C; Zhang X; Fu W; Shi L; Liu G
BMJ Open; 2018 Dec; 8(12):e022711. PubMed ID: 30530472
[TBL] [Abstract][Full Text] [Related]
38. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
Naito T; Okayama T; Aoyama T; Ohashi T; Masuda Y; Kimura M; Shiozaki H; Murakami H; Kenmotsu H; Taira T; Ono A; Wakuda K; Imai H; Oyakawa T; Ishii T; Omori S; Nakashima K; Endo M; Omae K; Mori K; Yamamoto N; Tanuma A; Takahashi T
BMC Cancer; 2017 Nov; 17(1):800. PubMed ID: 29183277
[TBL] [Abstract][Full Text] [Related]
39. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D; O'Day K; Hertel N; Penrod JR; Manley Daumont M; Lees M
Popul Health Metr; 2018 Nov; 16(1):17. PubMed ID: 30477516
[TBL] [Abstract][Full Text] [Related]
40. Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers.
Yanwei L; Minghui F; Manman Q; Zhuchun Y; Dongying L; Zhanyu P
Curr Probl Cancer; 2018; 42(3):358-366. PubMed ID: 29731164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
